Table 5.
Hazard ratios and 95% confidence intervals for circulating hormones and gastric cancer by subsite in men from the UK-Biobank study
| CGC | NCGC | |||||
|---|---|---|---|---|---|---|
| Cases (N = 113) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | Cases (N = 57) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | |
| Glucose (mmol/L) | ||||||
| < 4.7 | 30 | Reference | Reference | 15 | Reference | Reference |
| 4.7–5.2 | 29 | 0.94 (0.55–1.62) | 0.97 (0.56–1.67) | 16 | 1.12 (0.54–2.33) | 1.13 (0.54–2.36) |
| > 5.2 | 39 | 1.09 (0.65–1.82) | 1.07 (0.63–1.80) | 17 | 1.03 (0.50–2.13) | 1.07 (0.51–2.24) |
| P trend | 0.85 | 0.93 | 0.95 | 0.95 | ||
| Per 1-SD increase | 1.17 (0.99–1.38) | 1.13 (0.95–1.34) | 1.03 (0.79–1.35) | 1.06 (0.80–1.39) | ||
| HbA1c (mmol/mol) | ||||||
| < 33.6 | 28 | Reference | Reference | 16 | Reference | Reference |
| 33.6–37.0 | 26 | 0.86 (0.49–1.51) | 0.77 (0.43–1.37) | 13 | 0.83 (0.39–1.77) | 0.86 (0.40–1.85) |
| > 37.0 | 49 | 1.27 (0.76–2.11) | 0.99 (0.59–1.68) | 25 | 1.19 (0.60–2.33) | 1.24 (0.62–2.49) |
| P trend | 0.29 | 0.57 | 0.58 | 0.57 | ||
| Per 1-SD increase | 1.14 (0.94–1.37) | 1.04 (0.85–1.27) | 1.16 (0.93–1.46) | 1.19 (0.95–1.50) | ||
| CRP (mg/L) | ||||||
| < 0.8 | 22 | Reference | Reference | 13 | Reference | Reference |
| 0.8–1.9 | 40 | 1.42 (0.82–2.45) | 1.15 (0.66–2.00) | 16 | 1.17 (0.55–2.50) | 1.22 (0.57–2.63) |
| > 1.9 | 44 | 1.60 (0.94–2.72) | 1.10 (0.63–1.94) | 24 | 1.48 (0.73–3.03) | 1.58 (0.74–3.36) |
| P trend | 0.23 | 0.89 | 0.53 | 0.47 | ||
| Per 1-SD increase | 1.25 (1.03–1.53) | 1.10 (0.88–1.37) | 1.21 (0.92–1.59) | 1.23 (0.93–1.64) | ||
| IGF-1 (nmol/L) | ||||||
| < 19.6 | 44 | Reference | Reference | 27 | Reference | Reference |
| 19.6–23.9 | 31 | 0.87 (0.53–1.43) | 0.93 (0.57–1.52) | 15 | 0.70 (0.37–1.33) | 0.69 (0.36–1.32) |
| > 23.9 | 31 | 0.99 (0.60–1.62) | 1.06 (0.64–1.75) | 11 | 0.50 (0.23–1.07) | 0.50 (0.23–1.08) |
| P trend | 0.85 | 0.89 | 0.18 | 0.17 | ||
| Per 1-SD increase | 1.00 (0.82–1.22) | 1.04 (0.85–1.27) | 0.77 (0.60–1.00) | 0.77 (0.59–1.00) | ||
| SHBG (nmol/L) | ||||||
| < 30.9 | 19 | Reference | Reference | 9 | Reference | Reference |
| 30.9–43.7 | 34 | 1.42 (0.79–2.55) | 1.68 (0.92–3.06) | 13 | 1.13 (0.47–2.71) | 1.11 (0.46–2.66) |
| > 43.7 | 46 | 1.43 (0.81–2.55) | 1.90 (1.04–3.47) | 26 | 1.95 (0.89–4.26) | 1.89 (0.84–4.27) |
| P trend | 0.41 | 0.11 | 0.14 | 0.18 | ||
| Per 1-SD increase | 1.16 (0.92–1.45) | 1.29 (1.02–1.64) | 1.38 (1.01–1.89) | 1.36 (0.98–1.90) | ||
| Testosterone (nmol/L) | ||||||
| < 10.2 | 38 | Reference | Reference | 16 | Reference | Reference |
| 10.2–13.2 | 32 | 0.83 (0.50–1.37) | 0.99 (0.59–1.65) | 11 | 0.59 (0.26–1.33) | 0.61 (0.27–1.39) |
| > 13.2 | 37 | 1.00 (0.62–1.62) | 1.28 (0.77–2.13) | 25 | 1.55 (0.82–2.92) | 1.58 (0.81–3.11) |
| P trend | 0.70 | 0.55 | 0.04 | 0.05 | ||
| Per 1-SD increase | 0.97 (0.79–1.19) | 1.08 (0.87–1.35) | 0.94 (0.72–1.23) | 0.91 (0.69–1.22) | ||
| Free testosterone (pmol/L) | ||||||
| < 181 | 48 | Reference | Reference | 19 | Reference | Reference |
| 181–227 | 27 | 0.68 (0.42–1.12) | 0.73 (0.44–1.20) | 20 | 1.39 (0.71–2.70) | 1.37 (0.70–2.68) |
| > 227 | 23 | 0.73 (0.42–1.27) | 0.82 (0.47–1.45) | 8 | 0.72 (0.31–1.71) | 0.73 (0.30–1.73) |
| P trend | 0.26 | 0.45 | 0.28 | 0.30 | ||
| Per 1-SD increase | 0.85 (0.70–1.03) | 0.90 (0.73–1.10) | 0.73 (0.58–0.91) | 0.71 (0.57–0.89) | ||
aCrude model was stratified on age, center and town send deprivation index
bAdjusted model was based on crude model with further adjustment for education level, smoking, and body mass index
Not all of the cases will sum to the total due to missing data
CGC cardia gastric cancer, CI confidence interval, CRP C-reactive protein, HbA1c glycated hemoglobin, HR hazard ratio, IGF-1 insulin-like growth factor-1, NCGC non-cardia gastric cancer, SD standard deviation, SHBG sex hormone-binding globulin